



SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

July 30, 2026 12:30 PM EDT

MIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: [SABS](#)), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its second quarter 2026 financial results will be issued on the morning of Thursday, August 6, 2026. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates.

To access the live conference call, participants may register [here](#).

Conference Details:

Conference Date: Thursday, August 6, 2026

Conference Time: 8:30 AM ET

Conference Dial-in: 1-800-343-4136

International Dial-in: 1-203-518-9843

Conference ID: SABBIO

Conference Call Name: SAB BIO's Q2 2026 Earnings Call

Following the conference call, a replay of the audio webcast will be available under the [Investors & Media](#) section of the Company's website at [ir.sab.bio](#).

About SAB BIO

SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomal cattle, or Tc-Bovine, to produce hIgG. SAB BIO's drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. The Company's lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. SAB-142 is currently being evaluated in newly diagnosed Stage 3 autoimmune T1D patients in a registrational Phase 2b clinical trial called SAFEGUARD. For more information, visit [www.sab.bio](#). Additional details about SAFEGUARD are available at <https://safeguardstudy.com/>.

CONTACTS

Investors:

Christine Ryan

ir@sab.bio

Media:

Sheila Carlson

media@sab.bio